Emily E. White

Emily E. White

Auto-generated profile, based on publicly available information

Emily E. White

Fred Hutchinson Cancer Research Center , Seattle, WA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 December 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
DMDana K Mitchell
Dana K Mitchell
BBBreanne Burgess
Breanne Burgess
EWEmily White
Emily White
ASAbbi E Smith
Abbi E Smith
EPElizabeth A. Sierra Potchanant
Elizabeth A. Sierra Potchanant
SRSteven Rhodes
Steven Rhodes
Purpose: Plexiform neurofibromas (PNF) are benign peripheral nerve sheath tumors (PNST) associated with neurofibromatosis type 1 (NF1). Despite similar histologic appearance, these neoplasms exhibit diverse evolutionary trajectories, with a subset progressing to malignant peripheral nerve sheath tumor (MPNST), the leading cause of premature death in individuals with NF1. Malignant transformation of PNF often occurs through the development of atypical neurofibroma (ANF) precursor lesions characterized by distinct histopathologic features and CDKN2A copy-number loss. Although genomic studies have uncovered key driver events promoting tumor progression, the transcriptional changes preceding malignant transformation remain poorly defined. Experimental Design: Here we resolve gene-expression profiles in PNST across the neurofibroma-to-MPNST continuum in NF1 patients and mouse models, revealing early molecular features associated with neurofibroma evolution and transformation. Results: Our findings demonstrate that ANF exhibit enhanced signatures of antigen presentation and immune response, which are suppressed as malignant transformation ensues. MPNST further displayed deregulated survival and mitotic fidelity pathways, and targeting key mediators of these pathways, CENPF and BIRC5, disrupted the growth and viability of human MPNST cell lines and primary murine Nf1-Cdkn2a-mutant Schwann cell precursors. Finally, neurofibromas contiguous with MPNST manifested distinct alterations in core oncogenic and immune surveillance programs, suggesting that early molecular events driving disease progression may precede histopathologic evidence of malignancy. Conclusions: If validated prospectively in future studies, these signatures may serve as molecular diagnostic tools to augment conventional histopathologic diagnosis by identifying neurofibromas at high risk of undergoing malignant transformation, facilitating risk-adapted care.

20 June 2025 in Science Advances
Verified
Journal Article
Open access
MAMohannad Abu-Sultanah
Mohannad Abu-Sultanah
ZZZhuan Zhou
Zhuan Zhou
CJChunhui Jiang
Chunhui Jiang
DMDana K. Mitchell
Dana K. Mitchell
WBWaylan K. Bessler
Waylan K. Bessler
SRSteven Rhodes
Steven Rhodes
Plexiform neurofibromas (PNFs) are benign tumors of the peripheral nervous system that represent a major source of morbidity in neurofibromatosis type 1 (NF1). A substantial proportion of patients do not respond to current therapies or experience intolerable side effects. Transcriptomic characterization of murine and human PNF at bulk and single-cell resolution identified transforming growth factor–β (TGFβ) signaling as a key upstream regulator, driving aberrant basement membrane (BM) protein production by neoplastic Schwann cells and Fbs. Conditional TGFβ1 overexpression in Nf1 -deficient Schwann cells driven by Hoxb7- Cre promoted PNF growth and malignant transformation in vivo. Conversely, pharmacologic inhibition of the type I TGFβ receptor (TGFβRI) reduced PNF tumor burden in Nf1 mutant mice. Proteomic characterization of the extracellular matrix (ECM) showed reduced BM proteins upon TGFβRI inhibition. These findings implicate TGFβ as a potential therapeutic target in PNF and provide insights into the role of TGFβ signaling in orchestrating ECM dynamics in the PNF microenvironment.

9 November 2025 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Closed access
TZTing Zhang
Ting Zhang
XHXing Hua
Xing Hua
CMChirayu Mohindroo
Chirayu Mohindroo
XWXiaoyu Wang
Xiaoyu Wang
DDDiptavo Dutta
Diptavo Dutta
RSRachael Stolzenberg-Solomon
Rachael Stolzenberg-Solomon
Background: The associations between different types of diabetes, characterized by distinct pathophysiology and genetic architecture, and pancreatic ductal adenocarcinoma (PDAC) risk are not understood. Methods: We investigated associations of genetic susceptibility to type 2 diabetes (T2D), 8 T2D mechanistic clusters, type 1 diabetes (T1D), and maturity-onset diabetes of the young (MODY) with PDAC risk. We used genome-wide association study (GWAS) summary-level statistics for T2D (242 283 cases, 1 569 734 controls), T1D (18 942 cases, 501 638 controls), and PDAC (10 244 cases and 360 535 controls) in individuals of European ancestry. Results: Two-sample Mendelian randomization (MR) using the Robust Adjusted Profile Score (MR-RAPS) method indicated that genetically predicted T2D was associated with PDAC risk (OR = 1.10; 95% CI = 1.05 to 1.15), particularly the T2D obesity (OR = 1.28; 95% CI = 1.15 to 1.42) and lipodystrophy (OR = 1.25; 95% CI = 1.03 to 1.51) clusters. No association was observed for T1D with PDAC risk (OR = 1.01; 95% CI = 0.99 to 1.02). Pathway/gene-set analysis using the summary-based Adaptive Rank Truncated Product (sARTP) method revealed a significant association between the MODY gene-sets and PDAC risk (P = 1.5 × 10−8), which remained after excluding 20 known PDAC GWAS loci (P = 7.6 × 10−4). HNF1A, FOXA3, and HNF4A were the top contributing genes after excluding the previously identified GWAS loci regions. Conclusions: Our results from this genetic association study support that T2D, particularly the obesity and lipodystrophy mechanistic clusters, and MODY genomic susceptibility regions play a role in the etiology of PDAC.

22 September 2025 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Closed access
EEElmira Ebrahimi
Elmira Ebrahimi
SNSabine Naudin
Sabine Naudin
NDNiki Dimou
Niki Dimou
AMAna-Lucia Mayén
Ana-Lucia Mayén
MWMolin Wang
Molin Wang
PFPietro Ferrari
Pietro Ferrari
Background: This study aimed to investigate the association between alcohol consumption and squamous cell cancers of the upper aerodigestive tract (UADT), using data from 28 cohorts within the Pooling Project of Prospective Studies of Diet and Cancer (DCPP). Methods: Individual-level data from 2 365 437 participants were pooled. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using Cox models to quantify the association between alcohol consumption (g/day) and UADT cancer risk, adjusting for potential confounders. Analyses were conducted by sex, smoking status, geographic region, and alcoholic beverages. Results: Over a median follow-up of 15.5 years, 6903 UADT cancer cases were identified. Alcohol consumption was positively associated with UADT cancer risk overall. Even at intakes as low as 5–<15 g/day, the HR estimate was 1.12 (95% CI = 1.03 to 1.21) compared with the reference group (0.1-<5 g/day). The HR10 g/day (95% CI) was 1.16 (1.14 to 1.18) for women and 1.12 (1.11 to 1.13) for men (Pheterogeneity < .0001). HR10 g/day estimates were 1.14 (1.13 to 1.15) in current, 1.10 (1.09 to 1.12) in former, and 1.15 (1.12 to 1.18) in never smokers. Consistent UADT HR10 g/day estimates were observed across all beverage types. HR10 g/day estimates varied across geographic regions, with HR10 g/day (95% CI) equal to 1.15 (1.14 to 1.17) in Europe–Australia, 1.13 (1.11 to 1.15) in Asia, and 1.11 (1.09 to 1.12) in North America (Pheterogeneity < .0001). Conclusion: Alcohol consumption was associated with UADT cancer risk, irrespective of smoking status or beverage type. However, due to differential baseline risks, alcohol is expected to impact the UADT cancer burden more in smokers than never smokers. These findings support public health strategies to reduce alcohol consumption.

10 March 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
DMDana K. Mitchell
Dana K. Mitchell
KBKylee Brewster
Kylee Brewster
SMStavriani C. Makri
Stavriani C. Makri
JKJaffar Khan
Jaffar Khan
EAEric A. Albright
Eric A. Albright
WCWade Clapp
Wade Clapp
Purpose: Malignant peripheral nerve sheath tumor (MPNST) is the leading cause of premature death among individuals with neurofibromatosis type 1 (NF1), and the transcriptional aberrations that precede malignant transformation and contribute to MPNST tumorigenesis remain poorly defined. Alterations involving CDKN2A and components of PRC2 have been implicated as early drivers of peripheral nerve sheath tumor (PNST) evolution, but these events do not occur in all MPNST. Accordingly, emerging data have begun to highlight the importance of molecular-based stratification to improve outcomes in patients with NF1–PNST. Experimental Design: In this study, we perform an integrated analysis of multiple, independent datasets obtained from human patients with NF1 to gain critical insights into PNST evolution and MPNST heterogeneity. Results: We show that delta-like noncanonical Notch ligand 1 (DLK1) is significantly increased in MPNST and provide evidence that DLK1 overexpression may precede histologic changes consistent with malignancy. In complementary analyses, we find that serum levels of DLK1 are significantly higher in both mice and humans harboring MPNST compared with those without malignancy. Importantly, although DLK1 expression is increased in MPNST overall, through the integration of multiple, independent datasets, we demonstrate that divergent levels of DLK1 expression distinguish MPNST subsets characterized by unique molecular programs and potential therapeutic vulnerabilities. Specifically, we show that overexpression of DLK1 is associated with the reactivation of embryonic signatures, an immunosuppressive microenvironment, and a worse overall survival in patients with NF1–MPNST. Conclusions: Collectively, our findings provide critical insights into MPNST tumorigenesis and support prospective studies evaluating the utility of DLK1 tissue and serum levels in augmenting diagnosis, risk assessment, and therapeutic stratification in the setting of NF1–PNST.

15 May 2025
Verified
Other
Open access
DMDana K. Mitchell
Dana K. Mitchell
KBKylee Brewster
Kylee Brewster
SMStavriani C. Makri
Stavriani C. Makri
JKJaffar Khan
Jaffar Khan
EAEric A. Albright
Eric A. Albright
WCWade Clapp
Wade Clapp
GSE141438 MPNST vs adjacent normal tissue